
Michael D. Allen
Examiner (ID: 5951, Phone: (571)270-3497 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1671, 1642 |
| Total Applications | 608 |
| Issued Applications | 167 |
| Pending Applications | 65 |
| Abandoned Applications | 398 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15496295
[patent_doc_number] => 20200048336
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-13
[patent_title] => STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/286816
[patent_app_country] => US
[patent_app_date] => 2019-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12943
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16286816
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/286816 | STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY | Feb 26, 2019 | Abandoned |
Array
(
[id] => 14926057
[patent_doc_number] => 20190298666
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => PROMOTION OF T LYMPHOCYTE PROLIFERATION
[patent_app_type] => utility
[patent_app_number] => 16/281929
[patent_app_country] => US
[patent_app_date] => 2019-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16281929
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/281929 | PROMOTION OF T LYMPHOCYTE PROLIFERATION | Feb 20, 2019 | Abandoned |
Array
(
[id] => 16688379
[patent_doc_number] => 20210070855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RED BLOOD CELL AGLLUTINATION
[patent_app_type] => utility
[patent_app_number] => 16/964828
[patent_app_country] => US
[patent_app_date] => 2019-01-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16964828
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/964828 | ANTI-CD47 ANTIBODIES THAT DO NOT CAUSE SIGNIFICANT RED BLOOD CELL AGLLUTINATION | Jan 23, 2019 | Abandoned |
Array
(
[id] => 16853486
[patent_doc_number] => 20210154231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => METHOD FOR PRODUCING T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/054043
[patent_app_country] => US
[patent_app_date] => 2019-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8381
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054043
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054043 | METHOD FOR PRODUCING T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR | Jan 17, 2019 | Issued |
Array
(
[id] => 16398828
[patent_doc_number] => 20200339686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => BISPECIFIC ANTIBODY THAT BINDS CD3 AND ANOTHER TARGET
[patent_app_type] => utility
[patent_app_number] => 16/962180
[patent_app_country] => US
[patent_app_date] => 2019-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25127
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962180
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/962180 | BISPECIFIC ANTIBODY THAT BINDS CD3 AND ANOTHER TARGET | Jan 14, 2019 | Abandoned |
Array
(
[id] => 19536756
[patent_doc_number] => 12129297
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-29
[patent_title] => Antibodies against TIM3 and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/961545
[patent_app_country] => US
[patent_app_date] => 2019-01-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 94
[patent_figures_cnt] => 78
[patent_no_of_words] => 83880
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961545
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/961545 | Antibodies against TIM3 and uses thereof | Jan 10, 2019 | Issued |
Array
(
[id] => 15454545
[patent_doc_number] => 20200040097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/238752
[patent_app_country] => US
[patent_app_date] => 2019-01-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12482
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16238752
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/238752 | ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF | Jan 2, 2019 | Abandoned |
Array
(
[id] => 16598396
[patent_doc_number] => 20210024927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => CHIMERIC PROMOTER WITH HIGH TRANSCRIPTIONAL ACTIVITY IN T-CELLS
[patent_app_type] => utility
[patent_app_number] => 16/958625
[patent_app_country] => US
[patent_app_date] => 2018-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958625
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/958625 | CHIMERIC PROMOTER WITH HIGH TRANSCRIPTIONAL ACTIVITY IN T-CELLS | Dec 27, 2018 | Abandoned |
Array
(
[id] => 14210601
[patent_doc_number] => 20190117685
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/216714
[patent_app_country] => US
[patent_app_date] => 2018-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16216714
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/216714 | PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER | Dec 10, 2018 | Abandoned |
Array
(
[id] => 16993243
[patent_doc_number] => 20210231663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => MELANOMA CHECKPOINT INHIBITOR DETECTION AND TREATMENT
[patent_app_type] => utility
[patent_app_number] => 16/772512
[patent_app_country] => US
[patent_app_date] => 2018-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19029
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772512
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/772512 | MELANOMA CHECKPOINT INHIBITOR DETECTION AND TREATMENT | Dec 9, 2018 | Abandoned |
Array
(
[id] => 14406909
[patent_doc_number] => 20190169298
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-06
[patent_title] => RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/183300
[patent_app_country] => US
[patent_app_date] => 2018-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53285
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16183300
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/183300 | RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF | Nov 6, 2018 | Abandoned |
Array
(
[id] => 14929945
[patent_doc_number] => 20190300610
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-03
[patent_title] => VISTA ANTIGEN-BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/180949
[patent_app_country] => US
[patent_app_date] => 2018-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55785
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16180949
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/180949 | VISTA ANTIGEN-BINDING MOLECULES | Nov 4, 2018 | Abandoned |
Array
(
[id] => 16343970
[patent_doc_number] => 20200308620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => PREDICTING TUMOR SPECIFICITY OF TARGETED THERAPEUTICS USING ATOMIC FORCE MICROSCOPY (AFM)
[patent_app_type] => utility
[patent_app_number] => 16/759713
[patent_app_country] => US
[patent_app_date] => 2018-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759713
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/759713 | PREDICTING TUMOR SPECIFICITY OF TARGETED THERAPEUTICS USING ATOMIC FORCE MICROSCOPY (AFM) | Oct 25, 2018 | Abandoned |
Array
(
[id] => 13986583
[patent_doc_number] => 20190062449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-28
[patent_title] => USE OF ANTI-DKK-1 MONOCLONAL ANTIBODIES FOR TREATMENT OF LIVER CANCER
[patent_app_type] => utility
[patent_app_number] => 16/168467
[patent_app_country] => US
[patent_app_date] => 2018-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10369
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16168467
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/168467 | USE OF ANTI-DKK-1 MONOCLONAL ANTIBODIES FOR TREATMENT OF LIVER CANCER | Oct 22, 2018 | Abandoned |
Array
(
[id] => 14233437
[patent_doc_number] => 20190128891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-02
[patent_title] => METHOD, ARRAY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/161741
[patent_app_country] => US
[patent_app_date] => 2018-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16161741
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/161741 | METHOD, ARRAY AND USE THEREOF | Oct 15, 2018 | Abandoned |
Array
(
[id] => 14230619
[patent_doc_number] => 20190127482
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-02
[patent_title] => CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS
[patent_app_type] => utility
[patent_app_number] => 16/158377
[patent_app_country] => US
[patent_app_date] => 2018-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32032
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158377
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/158377 | CONJUGATES OF SURROGATE LIGHT CHAIN CONSTRUCTS | Oct 11, 2018 | Abandoned |
Array
(
[id] => 14182919
[patent_doc_number] => 20190111164
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-18
[patent_title] => HUMAN ANTIBODIES TO TN ANTIGEN
[patent_app_type] => utility
[patent_app_number] => 16/158688
[patent_app_country] => US
[patent_app_date] => 2018-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37176
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -74
[patent_words_short_claim] => 209
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16158688
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/158688 | Human antibodies to Tn antigen | Oct 11, 2018 | Issued |
Array
(
[id] => 13899059
[patent_doc_number] => 20190038734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-02-07
[patent_title] => METHODS FOR MONITORING AND TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/159134
[patent_app_country] => US
[patent_app_date] => 2018-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57762
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -85
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159134
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/159134 | METHODS FOR MONITORING AND TREATING CANCER | Oct 11, 2018 | Abandoned |
Array
(
[id] => 13871621
[patent_doc_number] => 20190032151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => METHODS FOR MONITORING AND TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/157853
[patent_app_country] => US
[patent_app_date] => 2018-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63112
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -106
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16157853
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/157853 | METHODS FOR MONITORING AND TREATING CANCER | Oct 10, 2018 | Abandoned |
Array
(
[id] => 18451618
[patent_doc_number] => 20230192897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => MULTISPECIFIC ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/754604
[patent_app_country] => US
[patent_app_date] => 2018-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 76119
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16754604
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/754604 | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain | Oct 8, 2018 | Issued |